Knockout models are useful tools to dissect the models of insulin resistance pathophysiology and genetics of insulin resistance

Clinical Endocrinology

Volumn 57, Issue 1, 2002, Pages 1-9

  Mauvais Jarvis, Franck ^a,b   Kulkarni, Rohit N ^c   Kahn, C Ronald ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT COCHIN   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; INSULIN;

ANIMAL MODEL; BRAIN; DISEASE MODEL; GENE LOCUS; GENETIC ENGINEERING; GENETICS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE ACTION; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID METABOLISM; MULTIFACTORIAL INHERITANCE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LEPTIN; LIPID METABOLISM; LIVER; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE, SKELETAL; OBESITY; RECEPTOR, INSULIN; RECEPTORS, SOMATOMEDIN; RESEARCH DESIGN;

EID: 0036066970     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01563.x     Document Type: Review

References (65)

1. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
2. Insulin resistance due to mutations of the insulin receptor gene: An overview
3. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene
4. Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus
5. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene
6. Insulin-stimulated insulin secretion in single pancreatic β cells
7. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
8. Role of the brain insulin receptor in control of body weight and reproduction
9. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance
10. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles
11. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β)
12. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
13. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM
14. Pathogenesis of NIDDM. A balanced overview
15. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes
16. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis
17. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes
18. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85alpha
19. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
20. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality
21. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes
22. Mapping of the human insulin receptor substrate-2 gene, identification of a linked polymorphic marker and linkage analysis in families with Type II diabetes: No evidence for a major susceptibility role
23. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4
24. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse
25. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2
26. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance
27. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle
28. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4
29. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia
30. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes
31. Islet beta-cell specific disruption of the IGF-1 receptor leads to glucose intolerance and hyperinsulinemia without altering islet morphology
32. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines
33. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue
34. Insulin receptor substrate 3 is not essential for growth or glucose homeostasis
35. Hyperinsulinemia precedes insulin resistance in a trangenic mouse model of type 2 diabetes
36. Hyperinsulinemia in transgenic mice leads to insulin resistance, receptor down-regulation, and glucose intolerance
37. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: Usefulness of leptin for the treatment of obesity-associated diabetes
38. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes
39. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes
40. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction
41. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
42. Life without white fat: A transgenic mouse
43. Potential Role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes
44. Leptin-replacement therapy for lipodystrophy
45. The Gly972-> Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β-cells
46. Glucose transporters and insulin action: Implications for insulin resistance and diabetes mellitus
47. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling
48. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
49. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
50. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipody-strophic and ob/ob mice
51. Cellular mechanisms of insulin resistance
52. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes
53. The hormone resistin links obesity to diabetes
54. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1
55. Lilly Lecture. Molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene
56. Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease
57. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase
58. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase
59. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
60. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling
61. Disruption of IRS-2 causes type 2 diabetes in mice
62. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice
63. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity
64. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
65. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance